Rui Huang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Newly Diagnosed

Top Venues

Bone marrow transplantation

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Rui Huang, Honghua He, Xiaoli Xu, Xiaonan Lin, Ying Dong, Xiaotao Wang, Fang Jiang, Pengcheng Huang, Shuyi Mo, Zhenqian Huang, Yaya Wang, Hongfang Tao, Yaling Zheng, Ming Wu, Chuting Yang, Ziyu Zheng, Ying Zhao, Yuming Zhang, Yuhua Li
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Cancer (2024)
Rui Huang, Honghua He, Xiaoli Xu, Xiaonan Lin, Ying Dong, Xiaotao Wang, Fang Jiang, Pengcheng Huang, Shuyi Mo, Zhenqian Huang, Yaya Wang, Hongfang Tao, Yaling Zheng, Ming Wu, Chuting Yang, Ziyu Zheng, Ying Zhao, Yuming Zhang, Yuhua Li
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Cancer 130 (14) (2024)
Rui Huang, Honghua He, Xiaoli Xu, Xiaonan Lin, Ying Dong, Xiaotao Wang, Fang Jiang, Pengcheng Huang, Shuyi Mo, Zhenqian Huang, Yaya Wang, Hongfang Tao, Yaling Zheng, Ming Wu, Chuting Yang, Ziyu Zheng, Ying Zhao, Yuming Zhang, Yuhua Li
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Cancer 130 (14) (2024)
Rui Huang, Honghua He, Xiaoli Xu, Xiaonan Lin, Ying Dong, Xiaotao Wang, Fang Jiang, Pengcheng Huang, Shuyi Mo, Zhenqian Huang, Yaya Wang, Hongfang Tao, Yaling Zheng, Ming Wu, Chuting Yang, Ziyu Zheng, Ying Zhao, Yuming Zhang, Yuhua Li
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Cancer 130 (14) (2024)
Xiaoting Zhang, Yuyang Pang, Cong Wei, Dan Liang, Shaoxin Yang, Chong Zhao, Rui Huang, Lan Deng
Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes. Bone marrow transplantation (2023)
Xiaoting Zhang, Yuyang Pang, Cong Wei, Dan Liang, Shaoxin Yang, Chong Zhao, Rui Huang, Lan Deng
Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes. Bone marrow transplantation 59 (3) (2023)
Xiaoting Zhang, Yuyang Pang, Cong Wei, Dan Liang, Shaoxin Yang, Chong Zhao, Rui Huang, Lan Deng
Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes. Bone marrow transplantation 59 (3) (2023)
Kexiu Huang, Lei Wang, Yaling Zheng, Chunyan Yue, Xuedan Xu, Hongbo Chen, Rui Huang, Yu-Hua Li
PHF6 mutation is associated with poor outcome in acute myeloid leukaemia. Cancer medicine (2022)